Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Institutional & Insider Ownership
15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Neuphoria Therapeutics and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
Volatility & Risk
Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Neuphoria Therapeutics and Upstream Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 101.15%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 892.20%. Given Upstream Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Upstream Bio is more favorable than Neuphoria Therapeutics.
Valuation & Earnings
This table compares Neuphoria Therapeutics and Upstream Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $1.17 million | 16.09 | -$13.45 million | ($6.22) | -0.56 |
| Upstream Bio | $2.85 million | 57.46 | -$143.44 million | ($2.90) | -1.03 |
Neuphoria Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Upstream Bio beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
